Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33530437 | 0.94 | DRD2 (0.46) | DRD2TDP1CA12CA1CA2 | |
| SCHEMBL30878565 | 0.83 | CA12 (0.48) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL30878634 | 0.81 | SCN9A (0.44) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL30878583 | 0.77 | CA12 (0.47) | CA12CA1CA2CA9 | |
| SCHEMBL30878596 | 0.75 | PDK2 (0.48) | CA12CA1CA2CA9 | |
| SCHEMBL33530556 | 0.73 | RIPK1 (0.46) | DRD2CA12CA1CA2CA9 | |
| SCHEMBL33531934 | 0.70 | ESR1 (0.47) | DRD2 | |
| SCHEMBL12603045 | 0.69 | ALDH1A1 (0.56) | DRD2TDP1CA12CA1CA2 | |
| SCHEMBL3468734 | 0.69 | CA1 (0.56) | DRD2TDP1CA12CA1CA2 | |
| SCHEMBL19975481 | 0.69 | CA12 (0.52) | DRD2TDP1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | DRD2 2355/4885TDP1 3638/4885CA12 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.